Yale School Of Medicine
Providers must go beyond weight reduction when treating obesity
Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.
Analysis: Price of hemophilia A therapy would have to drop nearly 60% to be cost-effective
SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII for patients with severe hemophilia A without inhibitors, according to results presented at ASH Annual Meeting and Exposition.
BLOG: Realigning rehabilitation of patellofemoral instability with novel technology
3D printing is emerging as a transformative force spanning across multiple industries. In health care, this cutting-edge technology is revolutionizing the way we evaluate and treat our patients across many disciplines.
Black, Hispanic, Latino patients with ASCVD less likely to get optimal care
Despite population-wide improvements in use of lipid-lowering medication and cholesterol control since 1999, significant racial and ethnic disparities persist among patients with a history of atherosclerotic CVD, researchers reported.
VIDEO: ‘Don’t discount what patients tell you’ when approaching alopecia areata treatment
VIDEO: No data to support non-pharmacologic treatment options for alopecia areata
VIDEO: JAK inhibitors ‘set the stage’ for alopecia areata drug development
VIDEO: Treating alopecia areata holistically in clinical practice
Cigarette smoking declines among young adults, but e-cigarette use increases to new high
Cigarette smoking has decreased among young adults in the United States, but nearly 15% reported regularly using e-cigarettes in 2021, a level higher than previously reported, according to study findings published in JAMA Internal Medicine.
Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT
PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.